Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 18

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Atrial fibrillation+2

Recruiting

Study on Early vs. Late Restart of Anticoagulation with Edoxaban, Apixaban, and Warfarin for Patients with Chronic Subdural Hematoma and Atrial Fibrillation

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:HUS-Yhtymae

Myotonic dystrophy

Recruiting

Study on Long-Term Safety and Efficacy of VX-670 for Adults with Myotonic Dystrophy Type I

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Vx-670
  • Sponsor:Vertex Pharmaceuticals Inc.

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Comparison of TAK-881 and HyQvia for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Takeda Development Center Americas Inc.

Dementia Alzheimer's type

Recruiting

Study on ITI-1284 for Treating Agitation in Alzheimer's Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Iti-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Subarachnoid haemorrhage+1

Recruiting

Study on the Effectiveness of Lidocaine Hydrochloride and Sodium Chloride for Treating Headaches in Patients with Spontaneous Brain Bleeding

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Migraine

Recruiting

Study on the Safety and Effectiveness of Atogepant for Preventing Chronic Migraine in Children Aged 12 to 17

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Parkinson's disease

Recruiting

Study on the Safety and Effectiveness of NEU-411 for Patients with Early Parkinson's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Neuron23 Inc.

Lymphatic malformation+3

Recruiting

Study of RLY-2608 for Adults and Children with PIK3CA-Related Overgrowth and Malformations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RLY-2608
  • Sponsor:Relay Therapeutics Inc.

Migraine

Recruiting

Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Erenumab
  • Sponsor:Oslo University Hospital HF

Narcolepsy+1

Recruiting

Study on the Safety and Effects of ORX750 for Patients with Narcolepsy and Idiopathic Hypersomnia

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

Duchenne muscular dystrophy+1

Recruiting

Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Entrada Therapeutics Inc.

Psychotic disorder+2

Recruiting

Study on ITI-1284 for Treating Psychosis in Alzheimer's Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Iti-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.